Review Article ETS gene fusions and prostate cancer
Wei Huang, Michelle Waknitz
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, 1600 Highland Avenue, Madison WI 53792
Received May 10, 2009; accepted May 20, 2009; available online May 25, 2009
Abstract: Chromosomal rearrangements are common genetic alterations in solid tumors and hematologic neoplasias. Recently, gene fusions between erythroblastosis virus E26 transforming sequence (ETS) family of transcription factors and androgen-regulated, prostate-specific TMPRSS2 gene were detected in the majority of prostate cancers. Further studies have shown a diversity of TMPRSS2-ETS hybrid transcripts and heterogeneity of the fusion genes in multifocal prostate cancer. The role of these gene fusions in prostate carcinogenesis, the protein products associated with the variant fusion transcripts and their association with tumor morphology, stage, and clinical outcomes have also been studied. Additional data have demonstrated ETS gene fusions as a potential biomarker for diagnosing and stratifying prostate cancer patients. The following summarizes these recent advances. (AJTR905002).